Who Should Avoid Keytruda After Allergic Reactions?
Patients with a history of severe hypersensitivity reactions to pembrolizumab (Keytruda's active ingredient) or any of its components must not use it. The prescribing information explicitly contraindicates Keytruda in those cases due to risk of anaphylaxis or life-threatening allergic responses.[1]
What Counts as a Severe Allergic Reaction?
Severe reactions include anaphylaxis, angioedema, or any prior episode requiring medical intervention like epinephrine. Mild reactions, such as localized rash, may not preclude use but require close monitoring and premedication—consult a doctor to assess.[1][2]
What If You've Had Reactions to Similar Drugs?
Avoid Keytruda if you've had severe allergies to other PD-1/PD-L1 inhibitors (e.g., Opdivo/nivolumab or Tecentriq/atezolizumab), as cross-reactivity is possible. Case reports document hypersensitivity switching between these monoclonal antibodies.[3]
How Do Doctors Test for Allergies Before Starting?
Skin testing or graded challenge dosing isn't standard for biologics like Keytruda. Instead, oncologists review history and may desensitize in controlled settings for borderline cases, but true hypersensitivity history leads to alternatives.[2]
What Alternatives Exist for Allergic Patients?
Options include chemotherapy, targeted therapies (e.g., EGFR inhibitors for lung cancer), or other immunotherapies like CTLA-4 blockers (Yervoy/ipilimumab). Choice depends on cancer type and stage—e.g., for melanoma, combination regimens without pembrolizumab.[1]
[1] Keytruda Prescribing Information (Merck)
[2] FDA Label for Pembrolizumab
[3] Journal of Allergy and Clinical Immunology: Case Reports on PD-1 Inhibitor Hypersensitivity